Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus gasseri BNR17

What does the research say about Lactobacillus gasseri BNR17?

2 health outcomes synthesised

Research on Lactobacillus gasseri BNR17 currently spans 2 health outcomes, both supported by moderate evidence. The strongest area is weight management, with 3 studies (including 2 RCTs and 1 meta-analysis) showing a consistent small effect on reducing waist circumference in obese adults. No consistent effective dose has been reported across these trials due to incomplete reporting.

Strongest evidence: Two outcomes have moderate evidence strength. For reduced waist circumference, all 3 studies (2 RCTs and 1 meta-analysis) reported beneficial effects, with a predominantly small effect size. For reduced abdominal pain, all 3 RCTs found moderate-to-large beneficial effects in adults with constipation or irritable bowel syndrome, though sample sizes ranged from 24 to 55 participants.

Mixed or weaker evidence: No outcomes with low or very low evidence were identified in the current syntheses. All research to date shows consistent benefits without contradictory findings.

Effective dose patterns: Neither synthesis reported a consistent effective dose range. Dose and form information was not systematically reported across the available trials, making it impossible to identify a reliable dosing pattern from the current literature.

Population insights: The evidence for waist circumference is specific to obese adults, while abdominal pain benefits were observed in adults with functional constipation or irritable bowel syndrome (IBS). No pediatric or elderly population data are available from these syntheses.

Notable caveats: The main limitations across both syntheses include small sample sizes (24 to 55 for abdominal pain studies), lack of dose and form reporting, and insufficient replication in larger populations. All studies were RCTs, which strengthens reliability, but the evidence base remains limited.

Frequently asked

  • What is Lactobacillus gasseri BNR17 good for according to research?
    Research shows moderate evidence that Lactobacillus gasseri BNR17 may help reduce waist circumference in obese adults and reduce abdominal pain in adults with constipation or irritable bowel syndrome. All 3 studies for each outcome reported beneficial effects.
  • What dose of Lactobacillus gasseri BNR17 is typically used in studies?
    The available research syntheses do not report consistent effective doses due to incomplete reporting across trials. No specific dose range can be derived from the current evidence.
  • Who benefits most from Lactobacillus gasseri BNR17?
    Based on current evidence, obese adults appear to benefit most for waist circumference reduction, while adults with functional constipation or irritable bowel syndrome benefit for abdominal pain. Studies involved adult populations only, with no data on children or the elderly.
  • Are there caveats or limitations in the research on Lactobacillus gasseri BNR17?
    Yes. Key limitations include small sample sizes (24–55 for abdominal pain studies), lack of dose and form reporting, and need for replication in larger populations. While all studies were RCTs, the evidence base is still limited.
  • Does Lactobacillus gasseri BNR17 help with reducing waist circumference?
    Moderate evidence from 3 studies (2 RCTs and 1 meta-analysis) shows Lactobacillus gasseri BNR17 has a small beneficial effect on reducing waist circumference in obese adults. Two of three studies found statistically significant reductions.
  • Does Lactobacillus gasseri BNR17 help with reducing abdominal pain?
    All 3 randomized controlled trials found moderate-to-large beneficial effects of Lactobacillus gasseri BNR17 on reducing abdominal pain in adults with constipation or irritable bowel syndrome. However, sample sizes were small (24–55 total participants).
    Back to top